Teva Reports New Ecopipam Data in Pediatric Tourette

Teva Pharmaceutical Industries Ltd. (TEVA) presented new efficacy and safety findings for its investigational D1 antagonist ecopipam in pediatric Tourette Syndrome at the MDS Congress. The data included post hoc analyses and interim long-term open-label extension findings.